115 related articles for article (PubMed ID: 35720961)
1. Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future.
Hamayoun M; Abdulrazak I; Farid M; Malik MR; Mohamud MF
IJID Reg; 2022 Sep; 4():47-52. PubMed ID: 35720961
[TBL] [Abstract][Full Text] [Related]
2. Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study.
Jose D; Dhupdale N; Cacodcar JA; Kamat U
Curr Drug Saf; 2023; 18(4):516-527. PubMed ID: 35927820
[TBL] [Abstract][Full Text] [Related]
3. Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, India.
Kamble B; Bashar MA; Mishra CP
Cureus; 2022 Feb; 14(2):e21848. PubMed ID: 35273834
[TBL] [Abstract][Full Text] [Related]
4. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.
Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A
J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323
[TBL] [Abstract][Full Text] [Related]
5. Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey.
Kaur S; Singh A; Saini S; Rohilla L; Kaur J; Chandi A; Kaur G; Singh M; Kumar P; Soni SL; Kajal K; Naik NB; Malhotra P; Verma S; Gupta M; Devnani M; Das K; Pandav SS; Puri GD
Indian J Med Res; 2022 Jan; 155(1):123-128. PubMed ID: 35859438
[TBL] [Abstract][Full Text] [Related]
6. Active Symptom-Based Surveillance of Adverse Events Following Immunization Among Individuals Vaccinated with ChAdOx1 nCoV-19 Coronavirus Vaccine in a Tertiary Hospital of Kerala.
Jose M; Rajmohan P; Thomas J; Krishna S; Antony B; Gopinathan UU; Iyyapan EM; Porinchu RM; Jose P; Raphael L; Kuttichira P
Curr Drug Saf; 2022; 17(4):327-334. PubMed ID: 35135453
[TBL] [Abstract][Full Text] [Related]
7. Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study.
Kamal D; Thakur V; Nath N; Malhotra T; Gupta A; Batlish R
Med J Armed Forces India; 2021 Jul; 77(Suppl 2):S283-S288. PubMed ID: 34334895
[TBL] [Abstract][Full Text] [Related]
8. Adverse Events Following COVISHIELD and VERO CELL Vaccination Campaigns Against COVID-19.
Adhikari S; Maharjan J; Bhattarai S; Kunwar K; Agrawal S; Dangal RK; Chapagain RH; Bista TB; Bhattarai S
J Nepal Health Res Counc; 2024 Mar; 21(4):651-658. PubMed ID: 38616598
[TBL] [Abstract][Full Text] [Related]
9. Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study.
Subedi P; Yadav GK; Paudel B; Regmi A; Pyakurel P
PLoS One; 2021; 16(12):e0260638. PubMed ID: 34932553
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India.
Chakraborty A; Reval N; Kamath L
Cureus; 2022 Feb; 14(2):e21809. PubMed ID: 35291520
[TBL] [Abstract][Full Text] [Related]
11. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
Jeon M; Kim J; Oh CE; Lee JY
J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
[TBL] [Abstract][Full Text] [Related]
12. Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal.
Poudel KM; Shah N; Prakash M; Deo SK; Bhandari S; Poudel TR
BMC Infect Dis; 2022 May; 22(1):422. PubMed ID: 35505278
[TBL] [Abstract][Full Text] [Related]
13. Cohort event monitoring for safety signal detection in adult individuals 18 years and above after immunisation with coronavirus disease 2019 vaccines in Nigeria.
Osibogun AO; Shuaib FM; Adeyeye CM; Onajole AT; Ejembi CL; Banwat ME; Wright KO; Mohammed A; Adeleye OA; Yahya SJ; Ifeadike CO; Elemuwa UU; Bassey BE; Oluwole EO; Erinoso OA
Niger Postgrad Med J; 2023; 30(1):18-24. PubMed ID: 36814159
[TBL] [Abstract][Full Text] [Related]
14. Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea.
Jeon M; Kim J; Oh CE; Lee JY
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696204
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study.
Velhal GD; Kamath YV; Agrawal AS; Vora DS; Dwivedi VR
Indian J Community Med; 2022; 47(4):613-617. PubMed ID: 36742958
[TBL] [Abstract][Full Text] [Related]
16. ADR Profile of the Covishield Vaccine Among Healthcare Workers in a Tertiary Care Teaching Hospital in India.
Deb T; Garg R; Kaur M; Beniwal A; Gupta V
Curr Drug Saf; 2022; 17(4):344-349. PubMed ID: 35049437
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021.
Konu YR; Gbeasor-Komlanvi FA; Yerima M; Sadio AJ; Tchankoni MK; Zida-Compaore WIC; Nayo-Apetsianyi J; Afanvi KA; Agoro S; Salou M; Landoh DE; Nyansa AB; Boko E; Mijiyawa M; Ekouevi DK
Arch Public Health; 2021 Nov; 79(1):207. PubMed ID: 34819146
[TBL] [Abstract][Full Text] [Related]
18. ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago.
Gopaul CD; Ventour D; Thomas D
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335098
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and determinants of adverse events following ChAdOx1 nCoV-19 vaccination (COVISHIELD) - A retrospective cohort study among healthcare workers in central Karnataka, India.
Davalagi SB; Nayak VP; Ghose A; Marakatti SS; Kasturi ES; Maganahalli AS
J Family Med Prim Care; 2023 Nov; 12(11):2869-2874. PubMed ID: 38186765
[TBL] [Abstract][Full Text] [Related]
20. Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others.
Christou-Ergos M; Wiley KE; Leask J
Vaccine; 2023 Jan; 41(1):246-250. PubMed ID: 36446655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
